Document Detail


Pantoprazole: a proton pump inhibitor.
MedLine Citation:
PMID:  19938880     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, no drug-drug interactions have been identified with pantoprazole in numerous interaction studies. Overall, in the short-term (8-10 weeks) initial treatment of gastro-oesophageal reflux disease (a condition that occurs when the reflux of gastric contents causes troublesome symptoms and/or complications) and long-term (6-24 months) maintenance therapy, oral pantoprazole 20 or 40 mg/day demonstrated similar efficacy to omeprazole, lansoprazole and esomeprazole and greater efficacy than histamine type 2 receptor antagonists. Pantoprazole is also effective in treating and preventing NSAID-related gastric and gastroduodenal injury. The optimal adult oral dose for gastric acid-related disorders is pantoprazole 40 mg once daily. Although data are limited, pantoprazole 20 or 40 mg/day was effective and well tolerated in the treatment of acid-related disorders in children and adolescents. Pantoprazole was also well tolerated in adults with acid-related disorders in short- and long-term studies. Thus, pantoprazole is a valuable agent for the management of acid-related disorders.
Authors:
Luis Moreira Dias
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical drug investigation     Volume:  29 Suppl 2     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2009  
Date Detail:
Created Date:  2009-11-26     Completed Date:  2010-03-12     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  3-12     Citation Subset:  IM    
Affiliation:
Médico Gastroenterologista, Porto, Portugal. l.md@clix.pt
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Ulcer Agents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Drug Interactions
Gastroesophageal Reflux / drug therapy*
Humans
Peptic Ulcer / chemically induced,  drug therapy,  prevention & control
Proton Pump Inhibitors / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Recurrence / prevention & control
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Anti-Ulcer Agents; 0/Proton Pump Inhibitors; D8TST4O562/pantoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Temporal Proteomic Analysis Reveals Continuous Impairment of Intestinal Development in Neonatal Pigl...
Next Document:  Severe gastro-oesophageal reflux disease.